Indium in-111 pentetreotide kit
Indium in-111 pentetreotide kit: 1 brand, 1 generic; first approved Jun 02, 1994; generic available.
Generic available: 1 ANDA application approved.
Brand (NDA) products
- CURIUMNDA 0203141994
Approved strengths under this FDA application. Strength Dosage form Route Status TE 3mCi/ML INJECTABLE INJECTION Rx —
Generic (ANDA) products (1)
- INDIUM IN-111 PENTETREOTIDE KITSUN PHARM INDS INCANDA 2127852024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 3mCi/ML INJECTABLE INJECTION Discontinued —
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
Approvals span 1994–2024 across 2 FDA applications.
Indium in-111 pentetreotide kit: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Go beyond the database.
Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.